Loading
Liraglutide · Regulatory label update
U.S. Food and Drug Administration · June 2, 2026
An action by a regulator. Authoritative on labelling and availability.
The FDA approved a supplemental labeling change for Saxenda (liraglutide 6 mg/mL subcutaneous solution) on 2 June 2026. This regulatory record documents the approval action only and contains no clinical trial data, efficacy results, or safety findings.
Regulatory label update.
The FDA approved a supplemental labeling change for Saxenda (liraglutide 6 mg/mL subcutaneous solution) on 2 June 2026. This regulatory record documents the approval action only and contains no clinical trial data, efficacy results, or safety findings.
This record does not contain clinical trial results, efficacy data, or safety findings.
The source did not state who this applies to in practice.
FDA supplemental approval for labeling change to liraglutide (Saxenda); describes regulatory action only, not clinical trial evidence or efficacy data.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Drugs@FDA record for application NDA206321. This is a regulatory action record, not a clinical study. Brand name: SAXENDA. Active ingredient: LIRAGLUTIDE. Sponsor: NOVO. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-06-02. Products: SAXENDA, SOLUTION, SUBCUTANEOUS, LIRAGLUTIDE 18MG/3ML (6MG/ML).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.